NM_004360.5:c.1493A>C
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 1P and 4B. PM2_SupportingBS2
This summary comes from the ClinGen Evidence Repository: The c.1493A>C (p.Asp498Ala) variant is present at <1/100,000 alleles in the European non-Finnish subpopulation of the gnomAD cohort (1/113,758 alleles; PM2_Supporting; http://gnomad.broadinstitute.org). The variant has been seen in at least 10 individuals without DCG, SRC tumors, or LBC & whose families do not suggest HDGC (BS2; SCV000279435.9, SCV000637728.4). In summary, this variant meets criteria to be classified as likely benign based on the ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: PM2_Supporting, BS2. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10577544/MONDO:0007648/007
Frequency
Consequence
NM_004360.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDH1 | NM_004360.5 | c.1493A>C | p.Asp498Ala | missense_variant | Exon 10 of 16 | ENST00000261769.10 | NP_004351.1 | |
CDH1 | NM_001317184.2 | c.1310A>C | p.Asp437Ala | missense_variant | Exon 9 of 15 | NP_001304113.1 | ||
CDH1 | NM_001317185.2 | c.-56A>C | 5_prime_UTR_variant | Exon 10 of 16 | NP_001304114.1 | |||
CDH1 | NM_001317186.2 | c.-327A>C | 5_prime_UTR_variant | Exon 10 of 15 | NP_001304115.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152238Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251478Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135908
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461888Hom.: 0 Cov.: 32 AF XY: 0.00000275 AC XY: 2AN XY: 727246
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152238Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74372
ClinVar
Submissions by phenotype
not provided Uncertain:2
This variant is denoted CDH1 c.1493A>C at the cDNA level, p.Asp498Ala (D498A) at the protein level, and results in the change of an Aspartic Acid to an Alanine (GAC>GCC). This variant has not, to our knowledge, been published in the literature as being pathogenic or benign. CDH1 Asp498Ala was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Since Aspartic Acid and Alanine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. CDH1 Asp498Ala occurs at a position that is conserved across species and is located in cadherin 4 of the extracellular domain (Brooks-Wilson 2004, Figueiredo 2013). In silico analyses predict that this variant is probably damaging to protein structure and function. Based on currently available information, it is unclear whether CDH1 Asp498Ala is pathogenic or benign. We consider it to be a variant of uncertain significance. -
- -
Hereditary diffuse gastric adenocarcinoma Uncertain:1Benign:1
PM2; BS2 (PMID: 30311375) -
This sequence change replaces aspartic acid, which is acidic and polar, with alanine, which is neutral and non-polar, at codon 498 of the CDH1 protein (p.Asp498Ala). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This missense change has been observed in individual(s) with CDH1-related conditions (PMID: 36436516). ClinVar contains an entry for this variant (Variation ID: 234528). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
This missense variant replaces aspartic acid with alanine at codon 498 of the CDH1 protein. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in several families affected with breast, gastric, and other cancers (PMID: 36436516), with one family specifying a lobular breast cancer prior to age 55. This variant has been identified in 1/251478 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
CDH1-related diffuse gastric and lobular breast cancer syndrome Benign:1
The c.1493A>C (p.Asp498Ala) variant is present at <1/100,000 alleles in the European non-Finnish subpopulation of the gnomAD cohort (1/113,758 alleles; PM2_Supporting; http://gnomad.broadinstitute.org). The variant has been seen in at least 10 individuals without DCG, SRC tumors, or LBC & whose families do not suggest HDGC (BS2; SCV000279435.9, SCV000637728.4). In summary, this variant meets criteria to be classified as likely benign based on the ACMG/AMP criteria applied, as specified by the CDH1 Variant Curation Expert Panel: PM2_Supporting, BS2. -
Hereditary diffuse gastric adenocarcinoma;CN311521:CDH1-related diffuse gastric and lobular breast cancer syndrome Other:1
Variant interpreted as Uncertain significance and reported on 11-29-2018 by Lab Peter MacCallum Cancer Centre Pathology. GenomeConnect- No Stomach for Cancer assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at